HMG-CoA Reductase Inhibitors
Bruinvels Infarm Sweelincklaan
Published 2002 ·
Download PDFAnalyze on Scholarcy
This paper references
C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study
M. Mendall (1996)
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.
H. Cai (2000)
Atherosclerotic plaque rupture and thrombosis. Evolving concepts.
V. Fuster (1990)
Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels.
J. Isaacsohn (1994)
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
O. Ozdemir (2000)
Transcriptional regulation of the human apolipoprotein genes.
V. Zannis (2001)
Molecular Cloning and Functional Analysis of the Promoter of the Human Squalene Synthase Gene (*)
G. Guan (1995)
Helix-Loop-Helix Proteins: Regulators of Transcription in Eucaryotic Organisms
M. Massari (2000)
Atherosclerosis is an inflammatory disease.
R. Ross (1999)
Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes
田中 誠 (1994)
Sterol regulation of acetyl coenzyme A carboxylase promoter requires two interdependent binding sites for sterol regulatory element binding proteins.
M. M. Magaña (1997)
Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2.
A. Fra (2000)
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
M. Endres (1998)
Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid.
J. M. López (1996)
Nuclear import of sterol regulatory element-binding protein-2, a basic helix-loop-helix-leucine zipper (bHLH-Zip)-containing transcription factor, occurs through the direct interaction of importin beta with HLH-Zip.
Emi Nagoshi (1999)
Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study.
J. Ware (1996)
Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme
G. Gil (1985)
Pathogenesis of thrombosis in unstable angina.
J. Chesebro (1991)
Thrombotic thrombocytopenic purpura and simvastatin
L. Mccarthy (1998)
Kwiterovich PO (1996) Small, dense low-density lipoprotein particles and coronary
J Coresh (1996)
ABCG5/8 genes responsible for serum plant sterol increase during stativ treatment
TA Miettinen (2001)
Monitoring the progress of the 2010 target for coronary heart disease mortality: estimated consequences on CHD incidence and mortality from changing prevalence of risk factors: a report for the Chief Medical Officer
K. Mcpherson (2001)
Kjekshus J, for the Scandinavian Simvastatin Study Group (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
TA Miettinen (1997)
Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia
A. Notarbartolo (1995)
The evolving role of statins in the management of atherosclerosis.
C. Vaughan (2000)
Triglyceride-rich proteins isolated by selected affinity
ST Kunitake (1994)
Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes.
A. Ribeiro (1991)
Two Tandem Binding Sites for Sterol Regulatory Element Binding Proteins Are Required for Sterol Regulation of Fatty-acid Synthase Promoter*
M. M. Magaña (1996)
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
M. Albert (2001)
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
M. Davidson (1997)
DNA Binding Specificities and Pairing Rules of the Ah Receptor, ARNT, and SIM Proteins (*)
H. Swanson (1995)
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products.
X. Wang (1998)
Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
J. Borén (1998)
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
G. Martin (2001)
HLH106, a Drosophila Sterol Regulatory Element-binding Protein in a Natural Cholesterol Auxotroph*
J. Rosenfeld (1998)
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
A. Gotto (2000)
Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
I. Schmid (1995)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
P. Ridker (1998)
Promoter selective transcriptional synergy mediated by sterol regulatory element binding protein and Sp1: a critical role for the Btd domain of Sp1.
J. Athanikar (1997)
Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs.
R. Rawson (1997)
Differential expression of cytosolic and mitochondrial 3-hydroxy-3-methylglutaryl CoA synthases during adipocyte differentiation
J. M. López (2004)
Effects of the 3-hydroxy-3-methylglutary1-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-I and endothelial nitric oxide synthase in vascular endothelial cells
D Perez-Sala (1998)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
P. Ridker (2000)
Peripheral Blood Mononuclear Phagocyte Subpopulations as Cellular Markers in Hypercholesterolemia
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
B. Pitt (1999)
Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture
P. Moreno (1994)
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
I. Shimomura (1999)
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
J. Alfón (1999)
Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man.
H. Vanhanen (1992)
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
D. Nicholson (1995)
Protein-losing enteropathy associated with hypocomplementemia and anti-nuclear antibodies
A. Nakajima (2000)
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
P. Canner (1986)
Current and future treatment of hyperlipidemia: the role of statins.
M. Farnier (1998)
Autocatalytic Processing of Site-1 Protease Removes Propeptide and Permits Cleavage of Sterol Regulatory Element-binding Proteins*
P. Espenshade (1999)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)
The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.
G. Fingerle (1993)
The Instructive Role of Innate Immunity in the Acquired Immune Response
D. Fearon (1996)
Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Lisa J. Wilcox (1999)
Cdk inhibitors: on the threshold of checkpoints and development.
S. Elledge (1994)
Adipocyte differentiation: a transcriptional regulatory cascade.
R. Brun (1996)
p21 is a universal inhibitor of cyclin kinases
Y. Xiong (1993)
The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers
A. M. Meadowcroft (1999)
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
H. Kempen (1988)
Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.
M. Kimura (1997)
Alternative binding assay of GP IIb/IIIa antagonists with a nonradioactive labeling method of platelets.
J. Alfón (2001)
The Roles of Sterol Regulatory Element-binding Proteins in the Transactivation of the Rat ATP Citrate-Lyase Promoter*
Y. Moon (2000)
Hypercholesterolemia and platelets.
E. Tremoli (1993)
Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR
J. Ou (2001)
Regulation of intracellular cholesterol metabolism.
R. Sato (1995)
Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13.
X. Hua (1995)
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
G. O’Driscoll (1997)
Multiple Sequence Elements are Involved in the Transcriptional Regulation of the Human Squalene Synthase Gene*
G. Guan (1997)
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
M. Pfeffer (1999)
The acute phase response.
H. Baumann (1994)
Xol INXS: role of the liver X and the farnesol X receptors
E. Fayard (2001)
Effect of glucose on sterol regulatory element binding protein (SREBP)-I in pancreatic beta cells
M Laudes (2001)
Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies for coronary prevention. Atherosclerosis
D Wood (1998)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
P. Ridker (2001)
INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES
P. Richardson (1989)
Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase*
U. Laufs (1997)
Sterol-Regulated Release of SREBP-2 from Cell Membranes Requires Two Sequential Cleavages, One Within a Transmembrane Segment
J. Sakai (1996)
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.
M. Saleh (1995)
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
T. Anderson (1995)
Stimulation of bone formation in vitro and in rodents by statins.
G. Mundy (1999)
Statins and peripheral neuropathy
U. Jeppesen (1999)
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
S. Colli (1997)
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation.
S. Bhakdi (1999)
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia
H. Vanhanen (1992)
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
K. Pyoeraelae (1997)
Transcriptional regulation of adipogenesis.
E. Rosen (2000)
Enhanced upregulation of the Fc gamma receptor IIIa (CD16a) during in vitro differentiation of ApoE4/4 monocytes.
J. Stöhr (1998)
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin
J. Caro (1997)
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
M. Guerin (2000)
Molecular biology of atherosclerosis.
P. Libby (1997)
The pathogenesis of atherosclerosis: a perspective for the 1990s
R. Ross (1993)
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
T. Pedersen (1996)
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
D. Ganz (2000)
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Z. Chen (1991)
Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice.
X. Zhou (1999)
Differential Stimulation of Cholesterol and Unsaturated Fatty Acid Biosynthesis in Cells Expressing Individual Nuclear Sterol Regulatory Element-binding Proteins*
J. T. Pai (1998)
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
U. Laufs (1998)
Identification and characterization of a novel monocyte subpopulation in human peripheral blood.
B. Passlick (1989)
Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
M. Guerin (1995)
Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver.
I. Shimomura (1997)
Statins as a newly recognized type of immunomodulator
B. Kwak (2000)
Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia.
T. Gauthier (1995)
42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter
T. Südhof (1987)
Platelet Cytosolic Ca2+ and Membrane Dynamics in Patients With Primary Hypercholesterolemia
Kim-Hanh Le QuanSang (1995)
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
A. Lefer (2001)
Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.
A. Fernández-Ortíz (1994)
The primary prevention of coronary heart disease in women.
J. Rich-Edwards (1995)
Primordial prevention of cardiovascular disease through applied genetics.
R. Williams (1999)
Lipotoxicity of-Cells in Obesity and in Other Causes of Fatty Acid Spillover
R. Unger (2001)
LDL Downregulates CYP51 in Porcine Vascular Endothelial Cells and in the Arterial Wall Through a Sterol Regulatory Element Binding Protein-2–Dependent Mechanism
C. Rodríguez (2001)
Peroxisome proliferator-activated receptor gamma and the control of adipogenesis.
R. Brun (1997)
Nutritional and insulin regulation of leptin gene expression.
N. Iritani (2000)
Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching.
J. Frank (1989)
A Direct Role for Sterol Regulatory Element Binding Protein in Activation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Gene (*)
S. Vallett (1996)
Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line.
S. Niwa (1996)
Differential Transcriptional Regulation of the Human Squalene Synthase Gene by Sterol Regulatory Element-binding Proteins (SREBP) 1a and 2 and Involvement of 5′ DNA Sequence Elements in the Regulation*
G. Guan (1998)
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
A. Corsini (1999)
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.
J. Kim (1996)
Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
F. Bernini (1993)
Recurrent G-to-A substitution in a single codon of SREBP cleavage-activating protein causes sterol resistance in three mutant Chinese hamster ovary cell lines.
A. Nohturfft (1996)
Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain.
J. Kim (1995)
Histopathology of plaque rupture.
H. Ravn (1999)
A natural classification of the basic helix-loop-helix class of transcription factors.
W. Atchley (1997)
Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver.
Z. Sheng (1995)
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.
M. Aikawa (1998)
Cooperation by Sterol Regulatory Element-binding Protein and Sp1 in Sterol Regulation of Low Density Lipoprotein Receptor Gene (*)
H. Sanchez (1995)
Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver.
I. Björkhem (1987)
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
G. Dangas (1999)
Molecular cloning of the promoter for rat hepatic neutral cholesterol ester hydrolase: evidence for transcriptional regulation by sterols.
R. Natarajan (1998)
Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2).
A. Miserez (1997)
Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study
M. Lorgeril (1999)
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.
G. Huhle (1999)
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
S. Haffner (1999)
New Insights into Plaque Stabilisation by Lipid Lowering
P. Libby (2012)
Sterol Resistance in CHO Cells Traced to Point Mutation in SREBP Cleavage–Activating Protein
X. Hua (1996)
Thrombin functions and antithrombotic intervention.
J. Fenton (1995)
Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains.
A. Voronova (1990)
Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription
U. Laufs (2000)
Multiple sterol regulatory elements in promoter for hamster 3-hydroxy-3-methylglutaryl-coenzyme A synthase.
J. Smith (1988)
ADD-1/SREBP-1 is a major determinant of tissue differential lipogenic capacity in mammalian and avian species.
F. Gondret (2001)
Analysis of mouse retinal dehydrogenase type 2 promoter and expression.
X. Wang (2001)
Serum cholesterol in young men and subsequent cardiovascular disease.
M. Klag (1993)
On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety
S. Bhakdi (1995)
Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene.
J. Ericsson (1996)
Specificity in cholesterol regulation of gene expression by coevolution of sterol regulatory DNA element and its binding protein.
J. Athanikar (1998)
YY1 Is a Negative Regulator of Transcription of Three Sterol Regulatory Element-binding Protein-responsive Genes*
J. Ericsson (1999)
Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
J. Zambrana (1997)
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.
M. Essig (1998)
Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes.
V. Bazil (1991)
Cell cycle progression and cell growth in mammalian cells
A Zetterberg (1995)
Dietary stano I ester in statin-treated coronary patients with high basal cholesterol
H Gylling (1998)
Secular trends in stroke incidence and mortality.
J. Grotta (1993)
The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor
M. Brown (1997)
Failure to Cleave Sterol Regulatory Element-binding Proteins (SREBPs) Causes Cholesterol Auxotrophy in Chinese Hamster Ovary Cells with Genetic Absence of SREBP Cleavage-activating Protein*
R. Rawson (1999)
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
T. Bourcier (2000)
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.
Yasuko Kureishi (2000)
Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data.
R. Kronmal (1993)
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
Z. Massy (1996)
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
M. Bevilacqua (1997)
A new class of yeast transcriptional activators
J. Ma (1987)
Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
R. Salonen (1995)
Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway.
F. Vrtovsnik (1997)
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
M. T. Montero (2000)
Perforin-secreting killer cell infiltration in the aortic tissue of patients with atherosclerotic aortic aneurysm.
Y. Seko (1997)
Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
G. Vega (1990)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPSrrexCAPS
C. Berry (1998)
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
T. Pedersen (2000)
LPS and ceramide docking to CDI4 provokes differential raft domain clustering
A Pfeiffer (2001)
SREBP-I mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I
R Streicher (1996)
Pravastatin therapy and the risk of stroke.
Brett As (2000)
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
P. Ridker (1998)
The interaction of diltiazem with lovastatin and pravastatin
N. Azie (1998)
S‐nitroso‐glutathione inhibits platelet activation in vitro and in vivo
M. Radomski (1992)
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
M. Uehata (1997)
Effects of lovastatin on the immune system.
M. Muldoon (1997)
Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys.
L. Hale (1998)
Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.
Stephan Jacob (1999)
Identification of Liver X Receptor-Retinoid X Receptor as an Activator of the Sterol Regulatory Element-Binding Protein 1c Gene Promoter
T. Yoshikawa (2001)
Transcriptional Activation of the Stearoyl-CoA Desaturase 2 Gene by Sterol Regulatory Element-binding Protein/Adipocyte Determination and Differentiation Factor 1*
D. Tabor (1998)
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence.
M. R. Briggs (1993)
Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
C. Malmendier (1989)
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
P. Tontonoz (1994)
Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.
P. Shah (1995)
M. C. Guillin (1995)
Molecular bases of the acute coronary syndromes
P Libby (1995)
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
W. Koenig (1999)
Platelet function in hyperlipoproteinemia.
A. Carvalho (1974)
Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older
T. Harris (1988)
Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1.
B. Gauthier (1999)
Regulation of fatty acid synthase expression by cholesterol in human cultured cells.
Y. Kawabe (1996)
Matrix metalloproteinases and cardiovascular disease.
C. Dollery (1995)
Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport.
C. Bruce (1998)
Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
G. Vega (1988)
Pathophysiology of atherosclerosis: Development, regression, restenosis
M. Adams (2000)
Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells.
I. Shimomura (1997)
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
M. Aikawa (2001)
Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
A. Mohammadi (1998)
Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice.
J. Horton (1998)
Natural history and histological classification of atherosclerotic lesions: an update.
H. Stary (2000)
Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
A. Alberts (1990)
HLH106, a Drosophila transcription factor with similarity to the vertebrate sterol responsive element binding protein.
U. Theopold (1996)
Cholesterol in signal transduction.
J. Incardona (2000)
Coronary Prevention Study (WOSCOPS). Circulation
BG Brown (1993)
Noncholesterol Serum Sterols in Scandinavian Simvastatin Survival Study
Tatu Miettinen (1996)
Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
A. Gaw (1993)
Role for sterol regulatory element binding protein in the regulation of farnesyl diphosphate synthase and in the control of cellular levels of cholesterol and triglyceride: evidence from sterol regulation-defective cells.
S. Jackson (1996)
Scavenging, signalling and adhesion coupling in macrophages: implications for atherogenesis
G. Schmitz (1997)
Sterol-resistant transcription in CHO cells caused by gene rearrangement that truncates SREBP-2.
J. Yang (1994)
Discovery, biochemistry and biology of lovastatin.
A. Alberts (1988)
Composite co-activator ARC mediates chromatin-directed transcriptional activation
A. Näär (1999)
Thrombin and antithrombotics.
J. Fenton (1998)
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
S. Bellosta (1998)
Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol.
S. Colles (1996)
Atorvastatin-induced severe thrombocytopenia
M. L. González-Ponte (1998)
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
W. Kannel (1971)
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
S. Wassmann (2001)
Sterol Regulatory Element Binding Protein-1 Activates the Cholesteryl Ester Transfer Protein Gene in Vivobut Is Not Required for Sterol Up-regulation of Gene Expression*
R. A. Chouinard (1998)
Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Y. Arad (1990)
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase*
U. Laufs (1998)
Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
J. Plutzky (2000)
Do HMG-CoA Reductase Inhibitors Affect Fibrinogen?
J. Song (2001)
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization.
X. Wang (1993)
Effects of bile acid feeding and depletion on plasma and biliary squalene, methyl sterols and lathosterol.ln: G Paumgartner, A Stiehl, W Gerok (eds): Bile Acids and Lipids
TA Miettinen (1981)
Atherosclerosis: an inflammatory disease
G. Schmitz (2001)
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
I. P. Torra (2001)
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
T. Pedersen (1998)
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
S. Haffner (1998)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
T. Pedersen (2004)
Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
L. Weiner (1994)
The response-to-retention hypothesis of atherogenesis reinforced.
K. Williams (1998)
A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease.
G. Rothe (1999)
Direct medical costs of coronary artery disease in the United States.
M. W. Russell (1998)
DNA binding specificity and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter.
H. Kan (1999)
Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
H. Wada (1993)
C-reactive protein: binding to lipids and lipoproteins.
M. Pepys (1985)
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.
H. Ginsberg (1987)
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
D. Steinberg (1989)
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
C. Bustos (1998)
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
J. Dimitroulakos (1999)
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.
I. Shimomura (1998)
Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia.
C. Serrano (2001)
Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
W. Maerz (1999)
Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta.
Y. Bobryshev (1995)
Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study.
T. Hillen (2000)
Basal non-cholesterol sterols reveal a subgroup of 4S not benefitted by simvastatin-induced decrease of recurrent coronary events
T. Miettinen (1998)
D Ferro (1997)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
Effects of atorvastatin on early recurrent ischemic events in acute coro
S Leslie (2001)
Primary prevention of acute coronary events with lovastatin in men
W Kruyer (1998)
An immunohistochemical analysis of human aortic fatty streaks.
J. Munro (1987)
CBP Is Required for Sterol-regulated and Sterol Regulatory Element-binding Protein-regulated Transcription*
J. Ericsson (1998)
p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism.
A. Bist (2000)
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma.
M. Aikawa (1999)
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
U. Laufs (2000)
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
A. D. Marais (1997)
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
J. Germershausen (1989)
T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.
S. Stemme (1995)
The IL-1 receptor and Rho directly associate to drive cell activation in inflammation.
R. Singh (1999)
Multiple DNA elements for sterol regulatory element-binding protein and NF-Y are responsible for sterol-regulated transcription of the genes for human 3-hydroxy-3-methylglutaryl coenzyme A synthase and squalene synthase.
J. Inoue (1998)
Understanding thrombin and hemostasis.
J. Fenton (1993)
A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid
T. Stalker (2001)
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins
C. Murre (1989)
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.
H. Vanhanen (1995)
Prevention of primary islet isograft nonfunction in mice with pravastatin.
S. Arita (1998)
Hormone-sensitive lipase (Lipe): Sequence analysis of the 129Sv mouse Lipe gene
R. Sztrolovics (2009)
Atherosclerotic aortic gangliosides enhance integrin-mediated platelet adhesion to collagen.
F. Wen (1999)
Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization.
P. Libby (2000)
Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging.
S. Meisel (1998)
Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta.
J. Allen (1991)
K Brand (1994)
Simvastatin Survival Study (4S) group
K Pyorala (1997)
SREBP-I , a basic-helix-Ioop-helix-Ieucine zipper protein that controls transcription of the low density lipoprotein receptor
C Yokoyama (1993)
Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.
A. Vuorio (2000)
Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis.
X. Wang (1996)
Serum cholesterol levels and stroke mortality.
Z. Chen (1989)
Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes.
K. Schoonjans (2000)
Identification of Diazepam-binding Inhibitor/Acyl-CoA-binding Protein as a Sterol Regulatory Element-binding Protein-responsive Gene*
J. Swinnen (1998)
Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis
H. Kishikawa (2005)
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
C. Packard (1998)
The role of adaptive immunity in atherosclerosis.
G. Hansson (2000)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
J. Shepherd (1995)
Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1.
R. Scalia (1998)
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.
A. Endo (1976)
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.
T. Miettinen (1990)
Lovastatin induces apoptosis in malignant mesothelioma cells.
J. Rubins (1998)
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
K. Mitropoulos (1997)
Reductase inhibitor monotherapy and stroke prevention.
J. Crouse (1997)
Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.
J. Goldstein (1979)
CoA reductase was mevastatin (compactin, ML-236B), which was isolated from Penicillium citrinium
A. Endo (1976)
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
K. Koh (2000)
Sterol regulatory element-binding protein-1a binds to cis elements in the promoter of the rat high density lipoprotein receptor SR-BI gene.
D. Lopez (1999)
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
D. Cohen (1999)
Cholesterol Biosynthesis from Lanosterol
J. Kim (2001)
Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.
G. Levine (1995)
Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV‐infected patients
W. A. Nockher (1994)
Markov Models in Medical Decision Making
F. Sonnenberg (1993)
Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes
A. Nohturfft (2000)
Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.
T. Miettinen (2000)
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
S. Grundy (1985)
Diseases of liporegulation: new perspective on obesity and related disorders
R. Unger (2001)
STOP-hypertension: Swedish trial in old patients with hypertension.
B. Dahlöf (1986)
Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.
I. Kaneko (1978)
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Y. Rikitake (2001)
Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol.
H. Gylling (1997)
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.
A. Lefer (1999)
Hairpin Orientation of Sterol Regulatory Element-binding Protein-2 in Cell Membranes as Determined by Protease Protection *
X. Hua (1995)
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
C. B. Treasure (1995)
HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.
Z. Yang (2000)
Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro.
A. Näär (1998)
Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation.
A. Suits (1989)
Identification of Glycerol-3-phosphate Acyltransferase as an Adipocyte Determination and Differentiation Factor 1- and Sterol Regulatory Element-binding Protein-responsive Gene*
J. Ericsson (1997)
Kjekshus J for the Scandinavian Simvastatin Study Group (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
TA Miettinen (1997)
tors for myocardial infarction in a cohort of 5790 men. Atherosclerosis
F Oram (1996)
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-l and endothelial nitric oxide synthase in vascular endothelial cells
D Perez-Sala (1998)
and differentiation . factor associated with adipocyte determination ADD 1 : a novel helix-loop-helix transcription
P. Tontonoz (1993)
Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
J. Cutts (1989)
Domains of transcription factor Sp1 required for synergistic activation with sterol regulatory element binding protein 1 of low density lipoprotein receptor promoter.
L. Yieh (1995)
Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation.
D. Baldassarre (1997)
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
C. Weber (1997)
Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia
G. Daví (1992)
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
D. D. Illingworth (1984)
Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.
M. Davies (1993)
The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II
D. Bharadwaj (1999)
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.
R. Havel (1987)
Influence of cholesterol-lowering on plasma membrane lipids and function.
P. Lijnen (1996)
Cassette of eight exons shared by genes for LDL receptor and EGF precursor.
T. Südhof (1985)
Associations between change in C-reactive protein and serum lipids during statin treatment
T. Strandberg (2000)
Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis.
D. Steinberg (1997)
Single nucleotide resolution of sterol regulatory region in promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase.
T. Osborne (1991)
Yin yang 1 protein negatively regulates high-density lipoprotein receptor gene transcription by disrupting binding of sterol regulatory element binding protein to the sterol regulatory element.
W. Shea-Eaton (2001)
Topology of SREBP Cleavage-activating Protein, a Polytopic Membrane Protein with a Sterol-sensing Domain*
A. Nohturfft (1998)
Sterol-dependent Transcriptional Regulation of Sterol Regulatory Element-binding Protein-2*
R. Sato (1996)
Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia
BG Jakob (1992)
Pet al (1999) ADDI/SREBP-Ic is required in the activation of hepatic lipogenic gene expression by glucose
M Foretz (1999)
Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia
P. Ridker (2001)
Cholesterol metabolism during hypolipidemic treatment with inhibitors of cholesterol synthesis
TA Miettinen (1990)
Role of the thrombin receptor in development and evidence for a second receptor
A. Connolly (1996)
Regulated Intramembrane Proteolysis A Control Mechanism Conserved from Bacteria to Humans
M. Brown (2000)
Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition.
C. Mueller (1999)
Sterol Regulation of Fatty Acid Synthase Promoter
M. Bennett (1995)
Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol.
A. Bist (1997)
A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
C. Aguilar-Salinas (1997)
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
J. Musial (2001)
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
T. Kakuma (2000)
Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial
S. Lewis (1998)
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
D. M. Pickin (1999)
Translational Control of p27Kip1 Accumulation During the Cell Cycle
L. Hengst (1996)
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.
J. Frostegård (1999)
Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.
J. Horton (1998)
Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products.
Joerg Kreuzer (1991)
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
L. Goldman (1991)
Second-site Cleavage in Sterol Regulatory Element-binding Protein Occurs at Transmembrane Junction as Determined by Cysteine Panning*
E. A. Duncan (1998)
Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element.
T. Osborne (1988)
Conditional response of the human steroidogenic acute regulatory protein gene promoter to sterol regulatory element binding protein-1a.
L. Christenson (2001)
Effects of changes in fat, fish, and References reinfarction trial
ML Burr (1989)
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
TR Pedersen (1998)
Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin. (concluded).
R. Lawrence (1946)
Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training.
P. Thompson (1988)
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.
G. Wolbink (1996)
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.
E. Pau (1995)
Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins.
P. Frank (2001)
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
C. Aguilar-Salinas (1995)
Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions.
U. Landmesser (2000)
Enlarged Infarcts in Endothelial Nitric Oxide Synthase Knockout Mice are Attenuated by Nitro-L-Arginine
Z. Huang (1996)
SREBP-1 binds to multiple sites and transactivates the human ApoA-II promoter in vitro : SREBP-1 mutants defective in DNA binding or transcriptional activation repress ApoA-II promoter activity.
P. Pissios (1999)
Participation of innate and acquired immunity in atherosclerosis
L. Curtiss (2000)
Statins inhibit T-cell interactions with elastin.
A. Górski (1999)
Rho GTPases and signaling networks.
L. Van Aelst (1997)
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P. Ridker (1997)
Serum plant sterols and their relation to cholesterol absorption.
R. Tilvis (1986)
Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene.
T. Südhof (1987)
The anti-thrombotic effects of statins.
D. Kearney (1999)
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
L. Prosser (2000)
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood.
M. Brown (1999)
Initial drug therapy for hypertensive patients with hyperlipidemia.
W. Kannel (1989)
Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications
G. Watts (1995)
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
P. Dansette (2000)
Morbidity, medication, and functional limitations in very old age
E. Steinhagen-Thiessen (1999)
Effect of statin therapy on C-reactive protein levels
M. Albert (2001)
Sterol regulatory element binding protein-1a regulation of the steroidogenic acute regulatory protein gene.
W. Shea-Eaton (2001)
Elucidation of the role of plaque instability and rupture in acute coronary events
V Fuster (1995)
Evolution of bHLH transcription factors: modular evolution by domain shuffling?
Bernd Morgenstern (1999)
Coronary C-reactive protein distribution: its relation to development of atherosclerosis.
Y. Zhang (1999)
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.
A. Endo (1976)
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.
M. Tewari (1995)
Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes.
M. Foretz (1999)
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
F. Sacks (1998)
Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.
C. Ahnadi (1993)
New and classical risk factors--the Münster heart study (PROCAM).
G. Assmann (1997)
Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations.
M. C. Burleigh (1992)
Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
O. Tamai (1997)
Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.
C. V. Dang (1992)
Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.
M. Weinstein (1987)
Clinical-pathological correlations of coronary disease progression and regression.
V. Fuster (1992)
Sterol Regulation of 3-Hydroxy-3-Methylglutaryl-coenzyme A Synthase Gene through a Direct Interaction Between Sterol Regulatory Element Binding Protein and the Trimeric CCAAT-binding Factor/Nuclear Factor Y*
K. Dooley (1998)
Inhibition of Dietary Cholesterol Absorption During Lovastatin (Mevinolin) Treatment
T. Miettinen (1990)
Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β
勝又 直樹 (2002)
SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.
J. Oliner (1996)
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
J. Kuivenhoven (1998)
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
P. Serruys (1999)
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors.
A. Endo (1981)
Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis.
M. Frankenberger (1996)
Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway
J. Swinnen (2000)
Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.
H. Gylling (1996)
Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions
W. Mueck (2012)
Dimerization of Sterol Regulatory Element-Binding Protein 2 via the Helix-Loop-Helix-Leucine Zipper Domain Is a Prerequisite for Its Nuclear Localization Mediated by Importin β
Emi Nagoshi (2001)
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia
K. Parhofer (1993)
Cell cycle progression: new therapeutic target for vascular proliferative disease.
R. Braun-Dullaeus (1998)
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
J. R. Schaefer (1999)
Statins: within-group comparisons, statin escape and combination therapy
M. Tikkanen (1996)
Should there be a moratorium on the use of cholesterol lowering drugs?
G. Davey Smith (1992)
Sterol Response Element-binding Protein 1c (SREBP1c) Is Involved in the Polyunsaturated Fatty Acid Suppression of Hepatic S14 Gene Transcription*
M. Mater (1999)
Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men.
T. Strandberg (1991)
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
W. Qin (1992)
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
B. Jönsson (1996)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
The LDL receptor gene: a mosaic of exons shared with different proteins.
T. Südhof (1985)
Plaque instability--the real challenge for atherosclerosis research in the next decade?
A. Newby (1999)
Premature mortality from coronary heart disease. The Framingham study.
T. Gordon (1971)
SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element.
X. Hua (1993)
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
J. Larosa (1999)
Current perspectives on statins. Circulation
M Miettinen (2000)
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ
J. Repa (2000)
HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal Macrophages
Incidence and Risk Factors for Stroke in an Occupational Cohort The PROCAM Study
K. Berger (1998)
Lovastatin increases apoprotein A-I levels in subjects with isolated reductions in high density lipoproteins
HN Ginsberg (1991)
Co-crystal structure of sterol regulatory element binding protein 1a at 2.3 A resolution.
A. Párraga (1998)
Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.
E. Emeson (1996)
Generalized immune activation in pulmonary tuberculosis: co‐activation with HIV infection
G. Vanham (1996)
Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications
J. Willerson (1989)
T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse.
H. Dansky (1997)
Transcriptional Regulation of the ATP Citrate-lyase Gene by Sterol Regulatory Element-binding Proteins*
R. Sato (2000)
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study.
B. Brown (1995)
Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
S. Rao (1998)
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.
J. Crouse (1998)
Purification of an Interleukin-1 Converting Enzyme-related Cysteine Protease That Cleaves Sterol Regulatory Element-binding Proteins between the Leucine Zipper and Transmembrane Domains (*)
X. Wang (1995)
Purification and cDNA cloning of a second apoptosis-related cysteine protease that cleaves and activates sterol regulatory element binding proteins.
J. T. Pai (1996)
Platelet activation in unstable coronary disease.
D. Fitzgerald (1986)
Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene.
H. Shimano (1997)
Regulated Cleavage of Sterol Regulatory Element Binding Proteins Requires Sequences on Both Sides of the Endoplasmic Reticulum Membrane (*)
X. Hua (1996)
Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated.
M. Aviram (1995)
Cleavage of Sterol Regulatory Element-binding Proteins (SREBPs) at Site-1 Requires Interaction with SREBP Cleavage-activating Protein
J. Sakai (1998)
Processes in atherogenesis: complement activation.
J. Torzewski (1997)
Effect of lovastatin on cardiovascular resource utilization and costs in the Airforce Coronaryrrexas Coronary Atherosclerosis Prevention Study (AFCAPSrrexCAPs)
AM Gotto (2000)
ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand.
J. Kim (1998)
Production of C-reactive protein and risk of coronary events in stable and unstable angina
E. Haverkate (1997)
CD40 and CD154 in cell-mediated immunity.
I. Grewal (1998)
Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands.
R. DeBose-Boyd (2001)
Changes in risk factors and the decline in mortality from cardiovascular disease.
R. M. Norris (1990)
Cleavage Site for Sterol-regulated Protease Localized to a Leu-Ser Bond in the Lumenal Loop of Sterol Regulatory Element-binding Protein-2*
E. A. Duncan (1997)
Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins.
J. Swinnen (1997)
Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1).
R. Sato (1994)
Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL.
J. Horton (1999)
Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin.
L. Hunakova (1997)
Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.
H. Shimano (1996)
Co-stimulation of Promoter for Low Density Lipoprotein Receptor Gene by Sterol Regulatory Element-binding Protein and Sp1 Is Specifically Disrupted by the Yin Yang 1 Protein*
M. Bennett (1999)
Nitric oxide: an endogenous modulator of leukocyte adhesion.
P. Kubes (1991)
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
M. Cuchel (1997)
Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men.
T. Miettinen (1989)
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
B. Desvergne (1999)
The Beaver Dam Health Outcomes study
D. Fryback (1993)
Synergistic Binding of Sterol Regulatory Element-binding Protein and NF-Y to the Farnesyl Diphosphate Synthase Promoter Is Critical for Sterol-regulated Expression of the Gene*
J. Ericsson (1996)
Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
J. Shepherd (2001)
Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pH
S. L. Schissel (1998)
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
D. Bilheimer (1983)
Protein kinases and cell cycle control.
J. Pines (1994)
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
G. Vega (1988)
Increased thrombotic vascular events after change of statin
M. Thomas (1998)
Nutrient regulation of gene expression by the sterol regulatory element binding proteins: increased recruitment of gene-specific coregulatory factors and selective hyperacetylation of histone H3 in vivo.
M. Bennett (2000)
Stabilization of atherosclerotic plaque during lipid lowering.
D. Müller-Wieland (1997)
Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.
H. Shimano (1997)
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease
I. U. Haq (1995)
Identification of Complexes between the COOH-terminal Domains of Sterol Regulatory Element-binding Proteins (SREBPs) and SREBP Cleavage-Activating Protein*
J. Sakai (1997)
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
D. D. Illingworth (1990)
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.
A. Henney (1991)
cells. A possible initiating event in atherosclerotic lesion formation
E Trogan (1995)
domain in the regulated degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase
RA DeBose-Boyd (1999)
Comparative chemistry, pharmacology and mechanism of action of the statins
A. Gaw (2003)
SREBP cleavage-activating protein causes sterol resistance in three mutant Chinese hamster ovary cell lines
J. Kotzka (1998)
SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis
X. Wang (1994)
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
R. Rosenson (1998)
Lipid advanced glycosylation: pathway for lipid oxidation in vivo.
R. Bucala (1993)
Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
A. Corsini (1996)
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
L. Lacoste (1995)
Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin.
H. Wada (1992)
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
M. Uusitupa (1992)
Regulation of HMG-CoA reductase.
V. Rodwell (1976)
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
J. Fisher (1999)
Cost-effectiveness of statins.
D. Huse (1998)
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization
M. Crisby (2001)
Sterol regulation of human fatty acid synthase promoter I requires nuclear factor-Y- and Sp-1-binding sites.
S. Xiong (2000)
Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
A. Corsini (1996)
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
E. Reihnér (1990)
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
J. Bergstrom (1998)
SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.
M. Matsuda (2001)
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
F. McTaggart (2001)
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
F. Raal (1997)
T-lymphocytes and monocytes in atherogenesis
G. Schmitz (2009)
Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol.
C. Opper (1995)
Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis.
G. Wick (1995)
Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.
T. Münzel (1995)
Recognition by Max of its cognate DNA trough a dimeric blHLH/Z
AR Ferre-D' Arnare (1993)
X-ceptors, nuclear receptors for metabolism
J. Auwerx (2000)
Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries.
G. Pasterkamp (1999)
EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE: Report from the Oslo Study Group of a Randomised Trial in Healthy Men
I. Hjermann (1981)
Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis
S McMahon (1998)
Regulation of the rat neutral cytosolic cholesteryl ester hydrolase promoter by hormones and sterols: a role for nuclear factor-Y in the sterol-mediated response.
R. Natarajan (1999)
Reversal of lovastatin‐mediated inhibition of natural killer cell cytotoxicity by interleukin 2
J. Cutts (1990)